Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
WuXi Biologics announced that the first GMP campaign in the new MFG3 facility was completed successfully.
read more
Wednesday, August 23, 2017
WuXi Biologics announces its unaudited interim results for the six months ended June 30, 2017.
read more
Tuesday, January 16, 2024
WuXi Biologics announced that its Research Service Unit has signed a research service agreement with BioNTech SE.
read more
WuXi Biologics has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a hub for pharmaceutical development.
read more
Wednesday, October 31, 2018
WuXi Biologics announced that construction has commenced on a Biologics Manufacturing Center of excellence (MFG8), in the city of Shijiazhuang, one hour train from Beijing.
read more
Friday, September 23, 2016
WuXi Biologics, an open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, has announced the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.
read more
Tuesday, December 02, 2025
WuXi Biologics announced that it has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to extend WuXi Biologics' global network and capabilities to the Middle East.
read more
Monday, November 01, 2021
WuXi Biologics a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product ...
read more
Tuesday, October 17, 2023
WuXi Biologics has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.
read more
WuXi Biologics announced the launch of WuXiHigh™2.0, a high-throughput formulation development platform designed for high concentration biologics. The platform enables protein concentrations of up to 230 mg/mL and achieves viscosity reduction by up ...
read more
Thursday, February 27, 2025
WuXi Biologics announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.
read more
WuXi Biologics announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's ...
read more
WuXi Biologics has received EMA GMP certificates for the production of Trogarzo™ at its cGMP DS and DP manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai.
read more
Wednesday, April 15, 2026
WuXi Biologics has obtained ISO 13485:2016 Medical Device Quality Management System certification, following an on-site audit that concluded with zero non-conformities.
read more
Wednesday, February 09, 2022
We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022.
read more